Company Valuation: Arecor Therapeutics plc

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 111.3 73.48 55.89 20.58 20.58 -
Change - -34% -23.94% -63.19% 0% -
Enterprise Value (EV) 1 93.02 60.68 49.14 17.25 20.38 23.27
Change - -34.77% -19.01% -64.9% 18.13% 14.17%
P/E ratio -14.8x -7.5x -6.52x -1.82x -2.73x -
PBR - 4.21x 5.87x 3.58x 31.8x -7.85x
PEG 0.2x -0.4x 0.5x -0.25x 0.1x -
Capitalization / Revenue 96.1x 30.6x 12.2x 3.76x 3.32x 4.18x
EV / Revenue 80.3x 25.3x 10.7x 3.15x 3.29x 4.72x
EV / EBITDA -14.8x -5.9x -5.66x -2.34x -4.35x -11.5x
EV / EBIT -14.4x -5.71x -5.36x -2.12x -3.76x -7.84x
EV / FCF - -5.48x -8.2x -2.04x -8x -9.52x
FCF Yield - -18.3% -12.2% -49.1% -12.5% -10.5%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -0.27 -0.32 -0.28 -0.3 -0.2 -
Distribution rate - - - - - -
Net sales 1 1.158 2.403 4.573 5.47 6.196 4.926
EBITDA 1 -6.268 -10.29 -8.679 -7.37 -4.689 -2.029
EBIT 1 -6.439 -10.63 -9.175 -8.15 -5.425 -2.968
Net income 1 -6.169 -9.26 -8.554 -8.032 -6.179 -
Net Debt 1 -18.32 -12.81 -6.752 -3.327 -0.1993 2.689
Reference price 2 4.0000 2.4000 1.8250 0.5450 0.5450 0.5450
Nbr of stocks (in thousands) 27,835 30,618 30,627 37,757 37,757 -
Announcement Date 4/25/22 4/20/23 5/16/24 - - -
1GBP in Million2GBP
Estimates

P/E ratio, Detailed evolution

Add to a list
P/E ratio (Y) EV / Sales (Y) EV / EBITDA (Y) Yield (Y) Capi.($)
-1.82x3.15x-2.34x-.--% 25.61M
52.73x7.17x25.48x0.73% 48.93B
28.61x3.29x13.72x-.--% 38.11B
90.32x11.31x40.73x0.26% 26.56B
22.5x2.27x10.87x-.--% 16.18B
14.36x4.74x9.1x-.--% 15.79B
-3.68x1.63x-1.5x-.--% 12.93B
63.26x9.65x27.83x0.43% 11.92B
30.17x5.18x23.71x-.--% 11.19B
Average 32.94x 5.38x 16.40x percentage-no-prefix 20.18B
Weighted average by Cap. 42.41x 5.96x 20.64x percentage-no-prefix
See all sector valuations

Year-on-year evolution of the PER

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. AREC Stock
  4. Valuation Arecor Therapeutics plc